 Xiamin-registered is a commercially available formulation of bachelina neurotoxin type A, BOTS slash A. It has been shown to be effective in reducing inflammation, glial scarring, and neuropathic pain following spinal cord injury, SCI. Previous studies have also found that injecting laboratory purified BOTS slash A into the spine of paraplegic mice after SCI can improve motor function and reduce pain. However, Xiamin-registered has been found to be less effective than laboratory purified BOTS slash A. The difference may be due to differences in the formulations or pharmacokinetics. Despite this, both treatments show promise in improving motor function and reducing pain following SCI. Further research is needed to better understand how these treatments work and how they can be used to best treat patients with SCI. This article was authored by Valentina Masturilli, Federica de Angelis, Valentina Vaca, and others.